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The last decade has witnessed a new chapter in the history of retrovirology. As of now, four human retroviruses have been identified and molecularly 
characterized. They are associated with a wide spectrum of human diseases including cancer, immunodefi~iency and neurological disorders. fly 
virtue of their clinical relevance, their novel genes and regulatory mechanisms these viruses have become the focal point of research in retrovirology. 
The study of these viruses is of fundamental importance in understanding the mechanisms leading to transformation of human cells and distortion 
of the immunological state. 
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1. INTRODUCTION 
Perhaps not as fundamental as the discovery of the 
DNA double helix, but most important to our 
understanding of the life cycle of retroviruses, has been 
the discovery of an RNA-dependent DNA polymerase, 
the reverse transcriptase [1,2]. Retrovisuses represent a 
unique class of RNA viruses which possess reverse 
transcriptase (RT), encoded by the viral genome. This 
enzyme catalyzes the transcription of the genomic RNA 
into a proviral DNA that gets integrated in the cellular 
genome as provirus. One of the important conse- 
quences of this discovery was that, since it is ubiquitous 
to retroviruses and since it is an enzyme, it allowed the 
detection of very low levels of such viruses. Soon after 
the discovery of reverse transcriptase in avian [l] and 
murine [2] retroviruses, Gallo et al. [3] made an exciting 
observation that human leukemic cells possess an RT 
activity which is biochemically similar to that of animal 
retroviruses. This activity was absent in mitotically 
stimulated normal human peripheral blood leucocytes. 
This led to the purification and characterization of cell- 
associated RT activity as a retroviral probe in human 
maiignant cells and tissues in several aboratories [4,.5] 
including our own [6-S]. However, no direct isolation 
of a biologically active human retrovirus was achieved. 
The major reason for this failure was probably the in- 
ability to grow the infected cells in culture, which would 
have been necessary for the successful virus detection. 
The discovery of T-cell growth factor (TCGF), now 
known as interleukin-2 (IL-2) [9] that allowed the long- 
term propagation in suspension culture of human T 
lymphocytes, was the major instrumentarium which led 
to the discovery of HTLV (human T-cell leukemia/lym- 
phoma virus}, the first human retrovirus [lo]. This 
knowledge of cultivating human T-cells in conjunction 
with sensitive RT assays has led to the discovery of three 
more human retroviruses, which all have T-cell tropism 
and require the CD4 molecule for infectivity. The ob- 
jective of this report is to provide a brief account of 
some novel features of human retroviruses which 
distinguish them from each other and from all known 
animal retroviruses. A number of excellent reviews on 
various aspects of human retroviruses, such as 
geographical distribution, clinical manifestations, 
genetic variability and immune dysfunction are avail- 
able in the literature [I I-151. 
2. NOMENCLATURE AND BIOLOGICAL 
CHARACTERISTICS 
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To date, we know of four well-characterized human 
retroviruses [I l-13] associated with a wide spectrum of 
clinical manifestations including cancer, im- 
munological disturbance and neurological disorders. By 
virtue of their extreme clinical relevance, their novel 
genes and regulatory mechanisms these viruses have 
become a focal point of research for biochemists, 
molecular biologists, immunoIogists, cell bioIogists, 
pathologists and clinicians, It is one of the few aspects 
of research with a concerted effort of such a large 
number of disciplines. Based on the pathological 
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manifestations we can divide human retroviruses into 2 
distinct groups: (i) viruses associated with T-cell 
leukemia and lymphotna (HTLV-I and HTL,V-II); and 
(ii) viruses associated with acquired immunodefjcienc~ 
syndrome (AIDS) (HIV-I and HIV-2). These viruses are 
approximately 90-100 nm in diameter. The members of 
the HTLV group are genetically related and exhibit a 
close sequence homology of 60-65”io, whiIe a com- 
parison of the HTLVs and HIVs shows that they share 
only 2-3O;o of the nucleic acid sequences common to 
each other. Another major difference between the two 
groups of viruses is in their rates of mutation, theil 
genomic diversity. For example, HIV-l or HIV-2 
isolates from different patients differ in their nucleotide 
sequence by up to 2OVro. This has led to a number of 
HIV strains (LAV, HTLV-IIIRE., HTLV-111~~~~ and 
many others) and HIV-2 strains (HIV-~K~~, 
HIV-~N~H.~, HIV-~SUL.~~~, etc.) with appreciable 
genomic diversity. However, HTLV isolates from dif- 
ferent regions of the world have almost identical 
nucleotide sequences. Another feature which 
distingLlishes the HTLV from the HIV group is their 
morphology. This led to subclassification of the viruses 
into different subfamilies. The HTLV-I and HTLV-II 
belong to type C retrovirus group and the oncoviridae 
subfamily, whereas the HIVs belong to the Lentiviridae 
subfamily. In spite of many distinguishing features, the 
two categories of viruses have several common pro- 
perities. Both types of viruses exhibit a tropism for T- 
cells and require the CD4’ molecule for infection. 
HIV-I and HIV-2 can also infect other cells such as 
macrophages, follicular dendritic cells, microglial cells, 
Langerhans cells and bone marrow myeloid precursor 
cells. Both types of viruses can remain latent in CD4 
cells for years, until immunologically activated. 
Secondly, and probably most important for both types 
of human retroviruses is the presence of regulatory 
genes. The proteins encoded by regulatory genes govern 
the up- and down-regulation of virus multiplication. 
The regulatory genes are novel to human retroviruses, 
not previously kno\vn in animal retroviruses. Thirdly, 
they have a common mode of transmission through 
blood by injury (sex), mother to child, intravenous drug 
abusers, blood transfusion, etc. Both types of viruses 
have their counterparts in primates; STLV-I (Simian T- 
cell lel~kemia/l~mpho~~a virus) is closely related to 
HTLV-I with almost 95% nucleic acid homology. 
Similary SIV (Simian immunodeficiency virus) isolates 
from macaques resemble closely HIV-2 with nucleic 
acid homology of 70-75%. The counterpart for HIV-1 
in primate is not yef knoM!n. 
The HTLV-I-associated diseases involve adult T-cell 
leukemia (ATL), tropical spastic paraparesis (TSP) or 
HTLV-I-associated myelopathy (HAM) and a mild type 
of immune deficiency. It is interesting that HTLV-I 
isotates causing TSP do not carry determinants of 
neurotropism in er?v or LTR-U3 that distinguish them 
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from isolates causing leukemia. The sequence variation 
is very small compared with that of HIV-1-ens [16]. 
HTLV-II is a variant of HTLV-I associated with hairy 
cell leukemia and in a small percent of cases it causes 
chronic T4-cell Iymphoma. There is a long latency 
period in the induction of the disease subsequent to 
seroconversion. The integration of provirus is not site 
specific. It varies from patient to patient, but in the 
same patient the integration site appears to be the same 
in all leukemic cells. 
In comparison to HTLVs, HIV-l infection leads to a 
progressive depletion of CD4-positive lymphocytes. 
Due to this effect it uas not possible to obtain enough 
of this virus needed for characterization. Although 
HIV-I (previously known as LAV) \vas first isolated by 
Barr&-Sinoussi et af. 1171, its first characterization was 
done by PopoviC et al. [18] using their o\vn isolate 
(previously known as HTLV-11111). This was due to fact 
that Popovii: et al. [18] succeeded in producing high 
quantities of their virus and different variants in a 
human T-cell leukemic pe~t??ff~7erl~ cell line which was 
resistant to the cytophatic effect of HIV-l. The deple- 
tion of CD4 cells causes profound impairment of the 
immune system resulting in the failure to eliminate op- 
portunistic infections caused by bacteria, viruses, fungi 
and parasites. Some HIV-infected persons develop 
neoplasms, the most predottlinantl~ occurring cancer 
being Kaposi’s sarcoma (KS). .Although DNA from KS 
does not show any HIV-l sequence nor the free virus, 
recent studies by Gallo et al. [ 191 implicate a direct role 
of HIV-I in the induction of KS. They succeeded in 
growing KS-derived spindel cells in long-time cultures. 
They found that the product of the tat-gene of HIV-I, 
obtained from a cloned sequence, could stimulate the 
growth of KS spindle cells by several-fold. This growth 
stimulatory effect was blocked by anti-tat protein IgG. 
The molecular mechanisms of this proliferative activity 
of the tat protein is not known. The neurologic 
manifestations of HIV-1 infection is seen in more than 
40% of ARC (AIDS-related-complex) and in AIDS pa- 
tients. More commonly, a progressive dementia and 
acute psychosis result. 
3. GENO~~IC ORGANISATION 
In addition to the usual retroviral genes, gig, pal and 
WV, which encode proteins that constitute the virus 
structure, human retroviruses possess a set of novel 
genes (Fig. I), the regulatory genes. The products of 
these genes are not present in the virus itself. The 
regulatory genes encode their proteins in the infected 
cell and these contribute to the expression of structural 
genes at different levels of molecular processing. The 
proteins of regulatory genes are coded by double spliced 
mRNA, a unique feature of human retroviruses, com- 
pared to animal retroviruses. 
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3.1. Human T-cell leukemia/lymphoma viruses A second gene called rex, regulator in region px, en- 
The most characteristic feature of HTLV-type 
genomes is the presence of a long open reading frame 
between the env gene and the 3 ’ -LTR (long terminal 
repeat). This region, called pX, encodes at least two 
gene products. The tax genes (Fig. 1) of HTLV-I and 
HTLV-II known as tax-l and tax-2, respectively encode 
proteins of molecular mass 40-42 kDa and 38 kDa. The 
tax protein is located in the nucleus and enhances viral 
transcription by activation of 21-base pair repeats in the 
viral LTR. Expression of tax protein activates a number 
of cellular genes, such as those coding for the CY chain of 
the high-affinity interleukin-2 receptor and interleukin 
2. IL-2 receptor activation requires tat expression but 
its constitutive expression in transformed cells does not 
require expression of any viral protein. The lax protein 
activates sequences to which the nuclear factor KB 
(NFxB) binds and thereby may induce a set of genes ex- 
pressed during T-cell activation. Tax protein can enfold 
several activities by influencing the genes activated by 
CAMP responsive factors, such as the activation of the 
fos proto-oncogene (201. The expression of the vimen- 
tin gene, a cytoskeletal growth-regulated gene, is ac- 
tivated in trans by the tax protein of HTLV-I [21]. 
codes a protein p27 in HTLV-I and ~25 in HTLV-II. 
This protein is essential for the expression of structural 
proteins. The rex protein is phosphorylated at serine 
and threonine which probably is important for its 
regulatory function. The rex protein functions in 
regulating the levels of unspliced to spliced viral 
mRNA. The r’ex protein is therefore regarded as a 
positive regulator of expression of structural proteins of 
HTLV-I. However, an overexpression of rex may lead 
to negative regulation. Thus HTLVs possess a self- 
regulatory mechanism to control their replication by the 
products of tax and rex genes [22]. Another protein en- 
coded by the pX region, the ~21” protein, has an amino 
acid sequence partially identical to that of ~27’~“. 
Like the human leukemia/fymphoma viruses, 
HTLV-I and HTLV-II, HIVs contain three structural 
genes (gag, pal and env) and a large number of ac- 
cessory genes (Fig. 1; Table I) which build up a self- 
regulatory system to control the replication of these 
viruses. The proteins encoded by the accessory genes 
are now well characterized (Table I) and this has helped 
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HTLV-I,II 
BLV 
HIV-2 
S’VMAC 
New name Function 
Table I 
Products of regulatory genes 
Molecular mass Former name 
HTL V-I and HTL V-II genes: 
ta.u, transactivator of viral tranwiption 
[L-LX2 
resi post-transcriptional regulators of structural proteins 
wk.2 
40-41 
38 
27 
25 
pX,x-lor,p40x,tat1 
tatz,TA 
pp27x.tel 
transactivator of viral transcription 14 
regulator of virion expression 19-20 
viron infectivity factor 23 
viral protein expression 15 
virus assembly and release (only in HIV-I) 
negative regulator of virus expression 27 
negative regulator (only in HIV-2 and SIV) 16(HIV);14(SIV) 
__ 
New nomenclature [57] for regulatory genes of T-lymphotropic retroviruses. 
tat-3,tat,TA 
art,trs 
sor,A,P ’ ,Q 
R 
3’orf,B,E’,F 
X 
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a great deal in understanding how these genes regulate 
virus replication. Now let us consider what kind of 
regulatory mechanisms are operated by these genes. 
Each of these operational processes could serve as a 
potential target for designing specific inhibitors of virus 
replication. For this reason, the functional role of each 
of these genes will be described separately. 
One of the regulatory genes located at the 3’-end of 
the viral genome, called nef has a negative effect on 
HIV replication. Deletions in the nef gene lead to a 5-10 
fold increase in replication of the virus. It encodes a 
polypeptide of 260 amino acids which is myristylated at 
the N-terminal, and also phosphorylated at a residue 
close to the N-terminal, like pp6’sarc. The question we 
may pose is, why is the product of this gene 
myristylated and at the same time phosphorylated? 
Phosphorylation at position 15 - a threonine - is also 
present in the EGF receptor. A second phosphorylation 
site involves serine. The phosphorylation at residue 15 
is enhanced by phorbol esters suggesting that this is 
mediated by protein kinase C, and finally, it has been 
shown that the 27 kDa protein exhibits GTP binding 
and GTPase activities [23]. The findings suggest that 
the nef gene exerts an indirect effect on virus replication 
by altering the level of expression of the viral receptor, 
T4 antigen. Thus, the loss of nefactivity may be critical 
to activation of HIV-I replication in vivo. It would be 
interesting to examine whether the presence or absence 
of a stop codon in the nef gene correlates with the stage 
of HIV-l infection in humans. Ahmad and Venkatesan 
[24] have reported that the repression induced by the 
nef protein is mediated by inhibition of transcription 
from HIV-l LTR, which contains a far upstream cis ele- 
ment between 340 and 154 nucleotides upstream of the 
RNA initiation site. There are two recent reports which 
have failed to confirm the down-regulation [25] and in- 
hibition of transcription [26] by the nef gene product. 
The role of the vif gene has been examined by a series 
of proviral genomes of HIV-l that either lacked the 
coding sequences for vif or contained point mutations 
in vif [27,28]. Normal amounts of gag-, PO/- and env- 
derived proteins were produced by the mutants, and 
assays in both lymphoid and nonlymphoid cells in- 
dicated that their transactivating capacity was intact 
and comparable with the wild-type. A mutant virus 
deficient in the vif gene was shown to produce virion 
particles normally [28]; however, the particles were 
lOOO-fold less infective than the wild-type. These data 
suggest that vif protein influences generations of infec- 
tious virus at a novel, post-transcriptional stage and 
that its action is independent of the regulatory genes tat 
and rev. 
Recently, Haseltine’s group [29] has characterized 
the vpr product and studied its function. The vpr gene 
encodes a 96 amino acid 15 kDa protein. This protein 
increases the rate of replication and accelerates the 
cytopathic effect of the virus in T-cells. The vpr protein 
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acts in tram to increase levels of viral protein expres- 
sion. This gene is highly conserved, not only among 
various HIV-1 isolates, but also in the distantly related 
ungulate lentivirus, \-isna. 
The next accessory gene, vpu, is present only in 
HIV-l, and absent in HIV-2 or SIV. This gene encodes 
a protein containing 81 amino acids. It is an integral 
membrane protein, localized in the perinuclear region 
of infected cells. In the absence of vpu, an accumula- 
tion of virion proteins in the cell associated with in- 
creased cytopathicity was observed [30]. T-cells infected 
with vpu mutant phenotype were characterized by a 
defect in virus release. However, the mechanisms in- 
volved in these activities remain still to be investigated. 
vpx is another accessory gene found in HIV-2 and 
SIV, but not in HIV-l. The striking conservation of vpx 
sequences among HIV-2, SIV,,,,,, and SIV,,,,, suggests a 
role for its product in viral replication, maturation or 
morphogenesis. Hobvever, recent studies with site- 
directed mutants [31] failed to designate any functional 
role to vpx protein. Immunoprecipitation analysis 
demonstrated a 16 kDa protein in cells infected with 
proviral HIV-2 DNA, but not in cells infected with mu- 
tant viruses. The amount of virus and viral structural 
proteins, and the infectivity of virus in different cell 
types was the same for vpx’ and vpY strains of 
HIV-2. 
The next accessory gene which is important for the 
expression of structural genes, particularly the env 
gene, is rev (regulator of virion expression). Because rev 
and tat genes overlap (in different reading frames) with 
each other, and with the envelope gene it has been dif- 
ficult to dissect completely the functional role of their 
products. Studies of fat or rev proviral deletion mutants 
have been difficult to interpret because of the possibili- 
ty of more than one functional unit being altered 
simultaneously and because other viral genes may in- 
fluence the results. However, site-directed mutagenesis 
of rev has shown that a chain termination mutation ear- 
ly in this gene results in an increase in transcription of 
viral mRNA as measured by nuclear transcription ex- 
periments, but only one major species of viral mRNA 
(1.8 kb) was detected, and little or no viral structural 
proteins were made. Thus the rev gene product is essen- 
tial for expression of viral structural proteins but, at the 
same time, may have a transregulatory negative effect 
on the transcription of regulatory genes [32]. On the 
other hand, a study by Rosen et al. [33] shows that se- 
quences located within the coding region of the 
envelope gene exert a negative effect on the expression 
of heterologous genes and that the negative effect of 
these sequences can be relieved by the rev gene product. 
rev protein regulates the export of viral structural 
mRNAs from the nucleus to the cytoplasm. Analysis of 
the subcellular localization revealed a marked ac- 
cumulation of re\’ protein in the nucleolus, suggesting a 
role for the nucleolus in this export process. Recently, 
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the sequence critical to nucleolar localization of rev 
protein has been determined 1341. In rev protein, the 
amio acids 38-39 and 45-51 are necessary for nucleolar 
localization. Mutations that markedly eliminate 
nucleolar localization markedly reduce rev function. 
Several studies indicate that rev protein exercises its 
functional activity by its specific interaction with struc- 
tural region in the mRNA, the rev-responsive lement 
(RRE); the RRE has been reported to be 223 nucleotides 
long f35-381. 
line, but spilled over to the cytoplasm in a stable high- 
expressing cell line, If the analogy holds for HIV-l, tat 
may first be found in the nucleus where it exerts its 
transcriptional effect, and then in the cytoplasm where 
it may activate a step or steps leading to protein produc- 
tion. Since tat is essential for HIV-1 replication, it pro- 
vides an attractive target for drug design. Chandra and 
coworkers have used this approach to develop in- 
hibitors of HIV-replication [46-481. 
Perhaps the most important of all the regulatory 
genes is the tat gene which is responsible for the expres- 
sion of all other genes. The term tat was coined to 
designate the transactivator of transcription. The tran- 
sactivating sequences have been localized to nucleotides 
5406-5607 of the HIV-l genome. This region contains 
the N-terminal segment of the tat reading frame, which 
potentially encodes a protein of 72 or 86 amino acids, 
depending upon the use of alternative RNA splicing 
pathways. The transactivator is the protein product of 
&at gene, which has been identified as a 15 kDa polypep- 
tide in HIV-l-infected cells requiring only 56 amino 
acids for activity. The domain essential for transactiva- 
tion has some characteristic features which are sug- 
gestive of a potential nucleic acid binding protein. First- 
ly, the functional domain in fat protein has an abun- 
dance of basic over acidic residues, which could 
mediate binding to the negatively charged backbone of 
the DNA segment, designated as TAR sequence located 
within the HIV-l LTR. Secondly the functional domain 
also contains a cluster of seven cysteine residues which 
may comprise a metal-binding domain important to 
nucleic acid binding. The differential ability of HIV-l 
(tat) and HIV-2 (tat) to transactivate some of the same 
LTRs [39] supports the binding of tat protein to specific 
sequences in LTR. 
4. HETEROGENEITY OF REVERSE 
TRANSCRIPTASE 
The reverse transcriptase (RT) encoded by the pal 
gene in most mammalian retroviruses is a monomeric 
protein with a molecular mass of 70-80 kDa [49]. The 
human immunodeficiency virus type 1 (HIV-l) has a 
reverse transcriptase that shares many biochemical pro- 
perties with other retroviruses [SO] yet shows some 
distinctive features [51,52]; in particular, the enzyme 
prefers Mg2 + over Mn2 + as the divalent cation and is 
characterized by the presence of two immunogenic 
polypeptides [53,54]. The two immunogenic polypep- 
tides, p66 and ~51, share a common N-terminus, sug- 
gesting that the smaller poIypeptide is derived from the 
larger by a proteolytic cleavage of the C-terminal end 
[54,55]. A third subunit, ~15, has also been identified 
and described as having RNase H activity [56]. The 
functional consequences of these processing events and 
the localization of activities to the resulting subunits is 
not yet clear. 
We have previously reported [51,52] that he catalytic 
activity of purified HIV-l RT can be resolved into two 
peaks of activities on a preparative isoelectric focusing 
column, one at pH 5.75 and the other at pH 6.25 (Fig. 
2A). 
The functional role of the tat gene has been studied We were interested to know whether this type of 
intensively [32,33,39-421, and the data can be sum- heterogeneity is unique to HIV-1 RT, or whether other 
marized as follows: analysis of both steady state viral human retroviruses and the AIDS-associated virus in 
messenger RNA and nascent transcribed RNA clearly monkeys also exhibit this property. We have purified 
demonstrate that the tat gene product plays a major role RT from HTLV-I, HTLV-II, HIV-2, simian im- 
in transcriptional activation, since its abrogation munodeficiency virus-African strain (SIV,,,) and 
resulted in a great reduction of both. Furthermore, tat bovine leukosis virus (BLV) under identical experimen- 
also has a role in post-transcriptional activation [43,443. tal conditions and subjected the purified enzyme frac- 
Feinberg et al. [43] reported that a mutant deleted in the tions to isoelectric focusing. In all these cases the en- 
splice acceptor site of tat expressed greatly reduced tat zyme activity was eluted in a single peak. This means 
activity. Cells transfected with this genome expressed that the type of biochemical heterogeneity observed in 
correspondingly lower levels of viral mRNA. Similarly, Fig. 2A is unique for HIV-l RT. Biochemical 
a mutant with a single amino acid change in tat, with characterization showed that both the enzymic activities 
reduced transactivation activity, was much more com- had the same ionic-dependency and preference for 
promised in protein expression than in viral mRNA ex- template-primer. We therefore, became interested in 
pression [32]. Therefore, tat may enhance both characterizing these activities serologically, using 
transcriptional and post-transcriptional events, depen- monoclonal antibodies to HIV-1 RT, secreted by 
ding upon the cellular localization of the tat protein. mouse/mouse hybridoma (CRT-l), generated in our 
For example, Felber et al. [453 showed that the trans- laboratory [53]. The antibody, designated as CRT-l, is 
activator protein of HTLV-1 was restricted to the not directed towards the catalytic site of RT, since it 
nucleus in a transiently transfected, low-expressing cell failed to neutralize the RT activity directly Fig. 2B 
419 
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Fig. 2. Profiles of DNA polymerase activities after electrofocusing of HIV-1 RT eluted from the phosphocellulose column (A), and serological 
profiles of each fraction against monoclonal antibody CRT-I to HIV-I RT (B). 
shows the results of immunoblotting where each frac- 
tion from the isoelectric focusing column was analyzed 
against the Mab CRT-l. The immunoblots of in- 
dividual fractions represent a specific pattern of im- 
munoreactivity. As shown in Fig. 2B, ~51 and p66 
species of RT are present in all the active fractions 
eluted in the region of pH 5.75 and pH 6.25. However, 
fractions 45-49, eluted at pH 6.25, contain in addition, 
large amounts of low-molecular mass subunits of iWr 
29 000, 32 000 and 40 000. The epitope mapping 
analysis by synthetic polypeptides from various regions 
of the pof gene suggests that the low-molecular mass 
subunits result from the N-terminal cleavage of the p5 1 
subunit. These subunits could only be separated by 
SDS-gel electrophoresis and detected by immunoblot- 
ting. So far, we have not succeeded in separating these 
subunits on chromatographic columns, suggesting that 
the subunits are complexed or conformationally arrang- 
ed in a way that their separation according to molecular 
420 
mass is not possible. The molecular mass of the active 
enzyme eluted from the chromatographic column 
(Sephacryl S-300) loaded \vith the mixture of subunits 
was estimated to be 100 kDa. 
5. THE MESSAGE 
The most important message of the last decade is that 
retroviruses are involved in diversified human diseases. 
Our knowledge about culturing human cells other than 
T cells, is incomplete. Q’e do not yet know what growth 
factors are needed specifically for growing different 
human cells in culture. The discovery of the T-cell 
growth factor [9], now known as interleukin-2, was a 
milestone which led to the discovery of two classes of 
human retroviruses, one associated with leukemia/lym- 
phoma and the other with immunodeficiency syn- 
drome. Both classes of viruses are T-cell tropic and re- 
quire the CD4 molecule for infection. The future of 
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human retrovirology is dependent on the development 
of technofogy for growing other human ceHs in culture. 
The recent discovery of a factor which helps maintain 
Kaposi’s sarcoma (KS) cells in culture [ 191 has helped us 
understanding the ro!e of transactivator protein (rat-l) 
in this disease. An intensive search for such factors is 
going in many laboratories, and it is to be hoped that 
with the adv~ncemcnt of this knowledge we may be able 
to discover new retroviruses associated with human 
diseases. 
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